[go: up one dir, main page]

NO932672L - Monokloane antistoffer mot elam-1 og anvendelser derav - Google Patents

Monokloane antistoffer mot elam-1 og anvendelser derav

Info

Publication number
NO932672L
NO932672L NO93932672A NO932672A NO932672L NO 932672 L NO932672 L NO 932672L NO 93932672 A NO93932672 A NO 93932672A NO 932672 A NO932672 A NO 932672A NO 932672 L NO932672 L NO 932672L
Authority
NO
Norway
Prior art keywords
elam
monocloan
applications
antibodies against
against elam
Prior art date
Application number
NO93932672A
Other languages
English (en)
Other versions
NO932672D0 (no
Inventor
Elisabeth Wayner
Mary L Phillips
Jeffrey L Winkelhake
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of NO932672D0 publication Critical patent/NO932672D0/no
Publication of NO932672L publication Critical patent/NO932672L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Blandinger og fremgangsmåter er tilveiebragt for inhiber- ing av inflammatoriske og andre sykdomsresponser formidlet av ELAM-1. Spesielt tilveiebringer den foreliggende oppfinnelse immunglobuliner som selektivt binder funksjonelle epitoper på ELAM-1 og blokkerer tilhefting av leukocytter til aktiverte endotelceller både in vitro og in vivo.
NO93932672A 1991-01-24 1993-07-23 Monokloane antistoffer mot elam-1 og anvendelser derav NO932672L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64587891A 1991-01-24 1991-01-24
US73303391A 1991-07-22 1991-07-22
PCT/US1992/000577 WO1992012729A1 (en) 1991-01-24 1992-01-23 Monoclonal antibodies to elam-1 and their uses

Publications (2)

Publication Number Publication Date
NO932672D0 NO932672D0 (no) 1993-07-23
NO932672L true NO932672L (no) 1993-09-23

Family

ID=27094802

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93932672A NO932672L (no) 1991-01-24 1993-07-23 Monokloane antistoffer mot elam-1 og anvendelser derav

Country Status (11)

Country Link
EP (1) EP0568631A4 (no)
JP (1) JPH06505253A (no)
AU (1) AU1269092A (no)
CA (1) CA2100681A1 (no)
IE (1) IE920206A1 (no)
IL (1) IL100764A0 (no)
NO (1) NO932672L (no)
NZ (1) NZ241399A (no)
OA (1) OA09809A (no)
SK (1) SK77393A3 (no)
WO (1) WO1992012729A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
ATE239506T1 (de) * 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5723116A (en) * 1995-01-06 1998-03-03 University Of South Florida Decreased mortality of severe acute pancreatitis following proximal cytokine blockade
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
ATE230614T1 (de) 1998-07-13 2003-01-15 Univ Texas Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
CN1356913A (zh) 1998-12-18 2002-07-03 杜邦药品公司 玻连蛋白受体拮抗剂药物
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
BRPI0917891A2 (pt) * 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
WO2019078344A1 (ja) * 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP4093508A1 (en) 2020-01-24 2022-11-30 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04501565A (ja) * 1988-11-14 1992-03-19 ブリガム・アンド・ウイメンズ・ホスピタル Ｅｌａｍ―１に特異的な抗体およびその用途
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Also Published As

Publication number Publication date
EP0568631A1 (en) 1993-11-10
NZ241399A (en) 1994-06-27
WO1992012729A1 (en) 1992-08-06
EP0568631A4 (en) 1995-04-05
NO932672D0 (no) 1993-07-23
CA2100681A1 (en) 1992-07-25
IL100764A0 (en) 1992-09-06
OA09809A (en) 1994-04-15
AU1269092A (en) 1992-08-27
JPH06505253A (ja) 1994-06-16
IE920206A1 (en) 1992-07-29
SK77393A3 (en) 1994-12-07

Similar Documents

Publication Publication Date Title
NO932672L (no) Monokloane antistoffer mot elam-1 og anvendelser derav
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
FR2382460A1 (fr) Complexe antigene proteine pour bloquer les reactions allergiques
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
MX2021002002A (es) Anticuerpos anti inmunorreceptor de celulas t con dominios ig y motivo inhibidor inmunorreceptor basado en tirosina (tigit).
NO924088L (no) Antistoffer, fremgangsmaate for deres fremstilling og anvendelse dera v
DK0724456T3 (da) CD40-Antistoffer
DE69637890D1 (de) Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
BR9508985A (pt) Ligantes de receptores x de ácido retinóico
NO20071717L (no) Anti-Fc-gamma-RIIB-reseptorantistoff og anvendelser av dette
DE69939820D1 (de) Internalisierende erbb2 antikörper
NO981745D0 (no) Monoklonalt antistoff BR110 og anvendelse av dette
NO20053389D0 (no) Antistoffer mot PD-1 og deres anvendelser.
DE60226486D1 (de) Selbstanordnende moleküle
DE69227456D1 (de) Nachweis von kollagenabbau -i(in vivo)
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
DK1242115T3 (da) Kemisk programmerbar immunitet
NO20021686D0 (no) Fremgangsmåter for fremstilling av målemolekyler i et transgent dyr og rensing av målmolekylet
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
NO20010747D0 (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
WO2021263167A3 (en) Il-10 muteins and fusion proteins thereof
IS5031A (is) Leysnir lymfótoxín-beta viðtakar, mótefni við andlymfótoxín viðtaka og mótefni við andlymfótoxín bindli sem lækningalyf við meðferð á ónæmissjúkdómum
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
YU85501A (sh) Upotreba blokirajućeg monoklonalnog antitela za vla-1 za pripremanje farmaceutskog preparata za tretiranje inflamatornih poremećaja